Streetbeat News

Assets

CURO

CURO Group Holdings has announced its plans to sell Flexiti for approximately C$55 million.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:13 pm

PRLD

Prelude Therapeutics reported Q2 losses of $(0.54) per share, beating the analyst consensus estimate of $(0.63) by 14.29%. This is a 6.9% increase over losses from the same period last year. The company's cash, cash equivalents, and marketable securities of $255M are sufficient to fund operations into 2026.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:12 pm

PAYO

Payoneer (NASDAQ:PAYO) has acquired Israel-based real-time data platform, Spott, to enhance its service offerings. Spott's AI technology will enable Payoneer to better understand and serve customers, particularly small and medium-sized businesses (SMBs). The first application of the technology will be on Payoneer's working capital products to enhance underwriting capabilities. Financial terms of the deal were not disclosed.

Portfolio Pulse from Happy Mohamed

August 04, 2023 | 1:10 pm

SNSE

Sensei Biotherapeutics reported Q2 cash, cash equivalents, and marketable securities of $78.8M. This provides the company with a cash runway into the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:07 pm

ABUS

Arbutus Biopharma reported cash, cash equivalents, and investments in marketable securities of $163.5M, providing a cash runway into Q1 2025. The company expects its 2023 net cash burn to range between $90M-$95M.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:07 pm

MORF

Morphic Holding reported Q2 losses of $0.92 per share, missing the analyst consensus estimate of $0.87 by 5.75%. This represents a 235.29% decrease from the same period last year. The company has over $730 million in cash and equivalents, extending its cash runway into the second half of 2027.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:03 pm

AVTX

Avalo Therapeutics has disclosed that it had approximately $6.3 million in cash as of June 30, 2023.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:03 pm

ABL

BENF

EEFT

PAYS

RELI

The article lists the top 5 oversold financial stocks, which are considered undervalued and present a buying opportunity. The stocks are Beneficient (BENF), Reliance Global Group (RELI), PaySign (PAYS), Abacus Life (ABL), and Euronet Worldwide (EEFT). The companies' recent performance and RSI values are discussed.

Portfolio Pulse from Lisa Levin

August 04, 2023 | 1:02 pm

ALVR

AlloVir reported Q2 losses of $(0.48) per share, missing the analyst consensus estimate of $(0.44) by 9.09%. However, this is a 30.43% increase over losses of $(0.69) per share from the same period last year. The company's cash, cash equivalents, and short-term investments total $246.5M, providing a cash runway into 2025.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 12:59 pm

FULC

Fulcrum Therapeutics has announced the appointment of Alan Musso as its new Chief Financial Officer, effective from August 7, 2023.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 12:58 pm